Immune-Inflammatory Biomarkers Predict Cognition and Social Functioning in Patients With Type 2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: A 1-Year Follow-Up Study
Por:
Garés-Caballer M, Sánchez-Ortí JV, Correa-Ghisays P, Balanzá-Martínez V, Selva-Vera G, Vila-Francés J, Magdalena-Benedito R, San-Martin C, Victor VM, Escribano-Lopez I, Hernandez-Mijares A, Vivas-Lalinde J, Vieta E, Leza JC and Tabarés-Seisdedos R
Publicada:
2 jun 2022
Ahead of Print:
2 jun 2022
Resumen:
BackgroundSystemic, low-grade immune-inflammatory activity, together with social and neurocognitive performance deficits are a transdiagnostic trait of people suffering from type 2 diabetes mellitus (T2DM) and severe mental illnesses (SMIs), such as schizophrenia (SZ), major depressive disorder (MDD), and bipolar disorder (BD). We aimed to determine if immune-inflammatory mediators were significantly altered in people with SMIs or T2DM compared with healthy controls (HC) and whether these biomarkers could help predict their cognition and social functioning 1 year after assessment. MethodsWe performed a prospective, 1-year follow-up cohort study with 165 participants at baseline (TB), including 30 with SZ, 42 with BD, 35 with MDD, 30 with T2DM, and 28 HC; and 125 at 1-year follow-up (TY), and determined executive domain (ED), global social functioning score (GSFS), and peripheral blood immune-inflammatory and oxidative stress biomarkers. ResultsParticipants with SMIs and T2DM showed increased peripheral levels of inflammatory markers, such as interleukin-10 (p < 0.01; eta(2)p = 0.07) and tumor necrosis factor-alpha (p < 0.05; eta(2)p = 0.08); and oxidative stress biomarkers, such as reactive oxygen species (ROS) (p < 0.05; eta(2)p = 0.07) and mitochondrial ROS (p < 0.01; eta(2)p = 0.08). The different combinations of the exposed biomarkers anticipated 46-57.3% of the total ED and 23.8-35.7% of GSFS for the participants with SMIs. LimitationsParticipants' treatment, as usual, was continued without no specific interventions; thus, it was difficult to anticipate substantial changes related to the psychopharmacological pattern. ConclusionPeople with SMIs show significantly increased levels of peripheral immune-inflammatory biomarkers, which may contribute to the neurocognitive and social deficits observed in SMIs, T2DM, and other diseases with systemic immune-inflammatory activation of chronic development. These parameters could help identify the subset of patients who could benefit from immune-inflammatory modulator strategies to ameliorate their functional outcomes.
Filiaciones:
Garés-Caballer M:
Teaching Unit of Psychiatry and Psychological Medicine, Department of Medicine, University of Valencia, Valencia, Spain
Sánchez-Ortí JV:
INCLIVA-Health Research Institute, Valencia, Spain
TMAP-Evaluation Unit of Personal Autonomy, Dependency and Serious Mental Disorders, University of Valencia, Valencia, Spain
Faculty of Psychology and Speech Therapy, University of Valencia, Valencia, Spain
Correa-Ghisays P:
INCLIVA-Health Research Institute, Valencia, Spain
TMAP-Evaluation Unit of Personal Autonomy, Dependency and Serious Mental Disorders, University of Valencia, Valencia, Spain
Faculty of Psychology and Speech Therapy, University of Valencia, Valencia, Spain
Center for Biomedical Research in Mental Health Network (CIBERSAM), Institute of Health Carlos III, Madrid, Spain
:
Teaching Unit of Psychiatry and Psychological Medicine, Department of Medicine, University of Valencia, Valencia, Spain
INCLIVA-Health Research Institute, Valencia, Spain
TMAP-Evaluation Unit of Personal Autonomy, Dependency and Serious Mental Disorders, University of Valencia, Valencia, Spain
Center for Biomedical Research in Mental Health Network (CIBERSAM), Institute of Health Carlos III, Madrid, Spain
Mental Health Unit of Catarroja, Valencia, Spain
Selva-Vera G:
Teaching Unit of Psychiatry and Psychological Medicine, Department of Medicine, University of Valencia, Valencia, Spain
INCLIVA-Health Research Institute, Valencia, Spain
TMAP-Evaluation Unit of Personal Autonomy, Dependency and Serious Mental Disorders, University of Valencia, Valencia, Spain
Center for Biomedical Research in Mental Health Network (CIBERSAM), Institute of Health Carlos III, Madrid, Spain
Vila-Francés J:
IDAL-Intelligent Data Analysis Laboratory, University of Valencia, Valencia, Spain
Magdalena-Benedito R:
IDAL-Intelligent Data Analysis Laboratory, University of Valencia, Valencia, Spain
San-Martin C:
INCLIVA-Health Research Institute, Valencia, Spain
TMAP-Evaluation Unit of Personal Autonomy, Dependency and Serious Mental Disorders, University of Valencia, Valencia, Spain
Department of Physiotherapy, University of Valencia, Valencia, Spain
:
Service of Endocrinology and Nutrition, University Hospital Dr. Peset, Valencia, Spain
Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain
Department of Physiology, University of Valencia, Valencia, Spain
:
Service of Endocrinology and Nutrition, University Hospital Dr. Peset, Valencia, Spain
:
Service of Endocrinology and Nutrition, University Hospital Dr. Peset, Valencia, Spain
:
Departament of Psychiatry, Mental Health Service of Manises, Valencia, Spain
Vieta E:
Center for Biomedical Research in Mental Health Network (CIBERSAM), Institute of Health Carlos III, Madrid, Spain
Barcelona Bipolar and Depressive Disorders Unit, Institute of Neurosciences, Hospital Clínic of Barcelona, University of Barcelona, IDIBAPS, Catalonia, Spain
Leza JC:
Center for Biomedical Research in Mental Health Network (CIBERSAM), Institute of Health Carlos III, Madrid, Spain
Department of Pharmacology and Toxicology, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain
:
Teaching Unit of Psychiatry and Psychological Medicine, Department of Medicine, University of Valencia, Valencia, Spain
INCLIVA-Health Research Institute, Valencia, Spain
TMAP-Evaluation Unit of Personal Autonomy, Dependency and Serious Mental Disorders, University of Valencia, Valencia, Spain
Center for Biomedical Research in Mental Health Network (CIBERSAM), Institute of Health Carlos III, Madrid, Spain
gold, Green Published
|